Pulmonary Remodeling in Equine Asthma: What Do We Know about Mediators of Inflammation in the Horse?

被引:17
|
作者
Barton, Ann Kristin [1 ]
Gehlen, Heidrun [1 ]
机构
[1] Free Univ Berlin, Equine Clin, Berlin, Germany
关键词
RECURRENT AIRWAY-OBSTRUCTION; BRONCHOALVEOLAR LAVAGE FLUID; EPITHELIAL LINING FLUID; HAY DUST SUSPENSION; C-REACTIVE PROTEIN; NF-KAPPA-B; SMOOTH-MUSCLE; MATRIX METALLOPROTEINASES; NEUTROPHIL RECRUITMENT; GENE-EXPRESSION;
D O I
10.1155/2016/5693205
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Equine inflammatory airway disease (IAD) and recurrent airway obstruction (RAO) represent a spectrum of chronic inflammatory disease of the airways in horses resembling human asthma in many aspects. Therefore, both are now described as severity grades of equine asthma. Increasing evidence in horses and humans suggests that local pulmonary inflammation is influenced by systemic inflammatory processes and the other way around. Inflammation, coagulation, and fibrinolysis as well as extracellular remodeling show close interactions. Cytology of bronchoalveolar lavage fluid and tracheal wash is commonly used to evaluate the severity of local inflammation in the lung. Other mediators of inflammation, like interleukins involved in the chemotaxis of neutrophils, have been studied. Chronic obstructive pneumopathies lead to remodeling of bronchial walls and lung parenchyma, ultimately causing fibrosis. Matrix metalloproteinases (MMPs) are discussed as themost important proteolytic enzymes during remodeling in human medicine and increasing evidence exists for the horse as well. A systemic involvement has been shown for severe equine asthma by increased acute phase proteins like serum amyloid A and haptoglobin in peripheral blood during exacerbation. Studies focusing on these and further possible inflammatory markers for chronic respiratory disease in the horse are discussed in this review of the literature.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] What Do We Know about Barley miRNAs?
    Volna, Adriana
    Bartas, Martin
    Pecinka, Petr
    Spunda, Vladimir
    Cerven, Jiri
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (23)
  • [2] What Do We Know About Rumen Development?
    Daniels, Kristy M.
    Yohe, Taylor T.
    23RD TRI-STATE DAIRY NUTRITION CONFERENCE, 2014, 2014, : 53 - 60
  • [3] What do we know about osmoadaptation of Yersinia pestis?
    Bontemps-Gallo, Sebastien
    Lacroix, Jean-Marie
    Sebbane, Florent
    ARCHIVES OF MICROBIOLOGY, 2022, 204 (01)
  • [4] Zebrafish and steroids: What do we know and what do we need to know?
    Tokarz, Janina
    Moeller, Gabriele
    de Angelis, Martin Hrabe
    Adamski, Jerzy
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2013, 137 : 165 - 173
  • [5] Chronic Heart Failure and Inflammation What Do We Really Know?
    Dick, Sarah A.
    Epelman, Slava
    CIRCULATION RESEARCH, 2016, 119 (01) : 159 - 176
  • [6] What do we really know about the external urethral sphincter?
    McCloskey, Karen D.
    Kanai, Anthony
    Panicker, Jalesh N.
    Hashitani, Hikaru
    Fry, Christopher H.
    CONTINENCE, 2024, 10
  • [7] What do we know about the mechanisms of aromatase inhibitor resistance?
    Chen, Shiuan
    Masri, Selma
    Wang, Xin
    Phung, Sheryl
    Yuan, Yate-Ching
    Wu, Xiwei
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2006, 102 (1-5) : 232 - 240
  • [8] What Do We Know about the Role of miRNAs in Pediatric Sarcoma?
    Kelly, Lorna C.
    Lazaro, Antonio
    O'Sullivan, Maureen J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (07) : 16593 - 16621
  • [9] Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first
    Cohen-Kaminsky, Sylvia
    Hautefort, Aurelie
    Price, Laura
    Humbert, Marc
    Perros, Frederic
    DRUG DISCOVERY TODAY, 2014, 19 (08) : 1251 - 1256
  • [10] Protein kinase C and cancer: what we know and what we do not
    Garg, R.
    Benedetti, L. G.
    Abera, M. B.
    Wang, H.
    Abba, M.
    Kazanietz, M. G.
    ONCOGENE, 2014, 33 (45) : 5225 - 5237